PRGO
BuySecond WindAI neutralPerrigo Company plc · Healthcare · Ireland · $1.9B cap · $42.8M/day traded
$15.45 +2.6% · close 12 Oct · scored 14 Oct
StockRank up 1.2 since 13 Oct.
Second Wind: Cheap and rising again, but the business does not yet earn the optimism.
Report expected 4 Nov: the next-year EPS estimate has risen 1.5% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for Perrigo Company plc (PRGO) is 73/100, ranked against 24,000+ stocks in 35 markets (Quality 33, Value 69, Momentum 66, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Perrigo is a leading maker of store-brand over-the-counter medicines and self-care products. It reported market-share gains but declining sales in its latest quarter, and it has been through a long restructuring after several strategic missteps. Store brands can benefit when consumers trade down, but the company has meaningful debt and a record of disappointing on turnarounds, so the case depends on execution rather than a proven compounder.
ABOUT PERRIGO COMPANY PLC
Read
Perrigo Company plc is a global consumer self-care company specializing in the development, manufacture, and marketing of over-the-counter (OTC) health and wellness products, including leading store brand and generic medicines. The company holds a dominant market position in the store brand OTC sector across the United States and Europe, leveraging its extensive manufacturing capabilities and deep retail partnerships. Perrigo's strategy focuses on providing affordable, high-quality self-care solutions to a broad consumer base.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.5B | 4.7B | 4.4B | 4.3B | -1.5% | 4.1B | 4.1B | 4.1B | -1.9% |
| EPS | -1.04 | -0.09 | -1.25 | -10.29 | — | -12.28 | — | — | — |
| Shares | 134.7M | 135.5M | 136.4M | 137.6M | +2.2% | 138.4M | — | — | — |
| Debt | 4.1B | 4.1B | 3.6B | 3.6B | -3.9% | 3.5B | — | — | — |
| Equity | 4.8B | 4.8B | 4.3B | 2.9B | -15.4% | — | — | — | — |
| Op CF | 307.3M | 405.5M | 362.9M | 238.5M | -8.1% | 196.1M | — | — | — |
| Inv CF | -2.0B | -77.5M | 78.8M | -75.4M | — | — | — | — | — |
| Fin CF | 421.6M | -187.2M | -611.0M | -220.5M | — | — | — | — | — |
75% above its 52-week low and back above a rising 50-day average.
Swung more than 71% of stocks we rank over the past year (56% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRGO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRGO | Perrigo Company plc(you) | $1.9B | 73 | Buy |
| ALKS | Alkermes plc | $7.1B | 58 | Hold |
| UPR.IR | Uniphar plc | $1.2B | 74 | Buy |
| GHRS | GH Research PLC | $1.8B | 29 | Sell |
| COPN.SW | Cosmo NV | $1.2B | 25 | Sell |
| JAZZ | Jazz Pharmaceuticals plc | $15.2B | 91 | Strong Buy |
| ICLR | ICON Public Limited Company | $12.6B | 47 | Hold |
| CMHC.SW | Cosmo N.V. | $1.1B | 19 | Strong Sell |
| AMRN | Amarin Corporation plc | $290M | 34 | Sell |
| PRTA | Prothena Corporation plc | $446M | 15 | Strong Sell |
Peer medians: ROE 2.1% · P/E 21.5x · Gross margin 55.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.